PDCD1 and neoplasm: In this trial, they deleted the TRAC and TRBC genes, which encode components of the endogenous T cell receptor, and the PDCD1 gene, which encodes the PD-1 protein, from the patients’ T lymphocytes to enhance anti-tumor immunity.